Palonosetron to prevent nausea and vomiting in children undergoing BMT: Efficacy and safety

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1663-1664

  Ripaldi, M ^a   Parasole, R ^a   De Simone, G ^a   D'Amico, M R ^a   Migliorati, R ^a   Zanotta, G ^a   Loffredo, G ^a   Petruzziello, F ^a   Poggi, V ^a  

^a SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PALONOSETRON;

ABSENCE OF SIDE EFFECTS; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ANTIEMETICS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; ISOQUINOLINES; MALE; NAUSEA; NEOPLASMS; QUINUCLIDINES; RETROSPECTIVE STUDIES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 78149467431     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.23     Document Type: Letter

References (10)

1. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 2009; 69: 515-533.
2. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al. Proposal for classification of the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109. (Pubitemid 27020563)
3. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of post-chemotherapy nausea and vomiting on health related quality oflife. Support Care Cancer 1997; 5: 307-313. (Pubitemid 27305081)
4. The Antiemetic Subcommittee of the Multinational Associa-tion of Supportive Care in Cancer (MASCC). Prevention of chemotherapy-and radiotherapy-induced emesis results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
5. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577. (Pubitemid 37304615)
6. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F et al. Palonosetron and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 2009; 17: 205-209.
7. Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 2010; 45: 123-127.
8. Kadota R, Shen V, Messinger Y. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: a stratified, double-blind, phase 3, randomized study. Proc Am Soc Clin Oncol 2007; 25(Suppl 18): S (abstract 9570) p. 543.
9. Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Marquez H, Villasis-Keever MA, Wanzke del Algel V et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Research 2008; 39: 601-606. (Pubitemid 352033608)
10. National Cancer Institute. Cancer Therapy Evaluation Pro-gram. Common Toxicity Criteria Version 2.0 April 30, 1999. http://ctep.info.nih.gov.